ANTIBODIES, VACCINES AND THERAPEUTIC VECTORS

Ciloa’s technology address several therapeutic areas through its three main applications : antibodies, vaccines, and therapeutic vectors.

The antibodies and therapeutic vectors based on our recombinant exosomes offer new therapeutic ways in oncology, infectiology, cardiology, genetic and neurological diseases. Exosome based vaccines will provide shields against viral pandemics.

Membrane proteins currently on Ciloa exosomes could be used to develop therapeutic or preventive solutions against many diseases such as :

  • Rheumatoid arthritis, inflammation
  • Metastasis
  • Ovarian cancer
  • Renal failure
  • Muscle loss, Duchenne’s disease
  • Colon Cancer
  • Osteosarcoma
  • Viral infections
  • Pancreatic cancer
  • Liver carcinoma
  • Prostate cancer
  • Lung cancer
  • Acute myeloid leukemia
  • Thyroid cancer
  • Breast cancer
  • Melanoma
  • Stomach cancer
  • Metastatic breast cancer

Ciloa is constantly pursuing its research work on the “undruggable” proteome to broaden the scope of targeted diseases. Our ambition is to develop our membrane targets of therapeutic interest on exosomes : 150 GPCRs, dozens of receptors kinases, several channels, transporters, and more…

OUR APPLICATIONS

ANTIBODIES

ANTIBODIES

Optimize antibodies targeting the most complex antigens with several major advantages.
VACCINES

VACCINES

Without adjuvants or viruses, Ciloa’s vaccines can be developed in a much shorter time frame than current technologies in the event of a pandemic.
THERAPEUTIC VECTORS

THERAPEUTIC VECTORS

Target therapeutic cell exosomes on specific cells to trigger a precise curative action.
Menu